Atlas Venture

CAMBRIDGE, Mass. & VIENNA, Austria--(BUSINESS WIRE)-- Fibrex Medical, a biopharmaceutical company focusing on cardiovascular and inflammatory diseases, today announced positive Phase II results for FX06, a peptide for the treatment of reperfusion injury - the damage to heart muscle that results from remedial treatment following a heart attack. The results will be presented at the ESC Congress today in Munich, Germany. The Phase II clinical trial of FX06 (F.I.R.E. study) in 234 patients with acute myocardial infarcts was completed in March 2008, with data indicating a statistically significant reduction in myocardial necrosis compared to placebo following intravenous application of FX06 during reperfusion treatment . FX06 is a peptide that binds to vascular endothelial (VE) cadherin, thereby inhibiting tissue inflammation and injury as well as preserving endothelial barrier function. These effects are deemed to be important for the prevention of the paradoxical additional damage to the heart muscle known as reperfusion injury. ...

WESTWOOD, Mass., Aug. 27 /PRNewswire/ -- Myvu Corporation today announced that it has signed an agreement with Airport Wireless making its line of Myvu personal media viewers available through 35 stores at 18 airports nationwide. Myvu will also be carried in 10+ airport locations slated to open this year. In addition to the Myvu Solo Plus already available through Airport Wireless, the retailer will carry Myvu Crystal, the newly introduced premium product, and Myvu Shades. Myvu media viewers transform portable media players into hands-free, full-screen private viewing experiences, offering the thinnest, lightest and most durable video eyewear incorporating the Myvu patented SolidOptex(R) technology. "Nothing demonstrates the need for on-the-go entertainment like air travel. The availability of our Myvu line through Airport Wireless and Techshowcase is a strategic extension to our brand and ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and fibrotic organ failure, announced today that its lead clinical candidate STX-100 has been granted orphan drug status by the US Food and Drug Administration ("FDA") for the treatment of chronic allograft nephropathy. Chronic allograft nephropathy (CAN), also known as chronic allograft dysfunction, is a fibrotic condition that ...

LONDON, UNITED KINGDOM -- (MARKET WIRE) -- 08/12/08 -- Myvu, the world's leading video eyewear provider, today announced that it has become a member of Forum Nokia PRO, a program that provides advanced technical, business development and marketing support to selected mobile software companies. As a member of Forum Nokia PRO, Myvu has the opportunity to further strengthen its relationship with Nokia, gain early access to Nokia technology and take advantage of specialized service and support provided by Nokia to help Myvu stand out in the marketplace. Forum Nokia PRO provides specialized support for advanced developer companies creating the next generation of software based on the Series ...

NEWTON, Mass.--(BUSINESS WIRE)-- SimpleTuition, Inc., the leading student loan comparison site for personalized student loan research, today announced that student lending products from several leading lending institutions - PNC Bank, Discover, Brazos, College Loan Corp., GradInvest, OneSimpleLoan, Axiom, and ScholarPoint - have joined the ranks of offerings at www.simpletuition.com. As the credit crunch puts the squeeze on student loan borrowers, the demand for student loan information and borrowing options is great than ever. With fewer ...